Clinical TrialJul 31, 2026, 07:01 AM
Tiziana Reports Up to 34% Reduction in Brain Inflammation for MSA Drug
AI Summary
Tiziana Life Sciences announced positive quantitative PET imaging results from the third patient in its Phase 2 clinical trial for intranasal foralumab in Multiple System Atrophy (MSA). The patient showed up to a 34% reduction in standardized uptake value (SUV) and a 26% reduction in standardized uptake value ratio (SUVR) in affected brain regions, indicating reduced neuroinflammatory activity. These findings are consistent with results from the first two patients, reinforcing confidence in the drug's potential for this neurodegenerative disorder which currently lacks approved disease-modifying treatments. The company plans further evaluation.
Key Highlights
- Third Multiple System Atrophy (MSA) patient in Phase 2 trial completed dosing with intranasal foralumab.
- Quantitative PET imaging showed up to 34% reduction in SUV in affected brain regions.
- Up to 26% reduction in SUVR was observed in clinically relevant brain areas.
- Results are consistent with the first two MSA patients, who showed similar reductions.
- Intranasal foralumab is a fully human anti-CD3 monoclonal antibody.
- MSA is a rare neurodegenerative disorder with no approved disease-modifying treatments.
Price Impact
More from TLSA